Tower Research Capital (TRC)’s Aardvark Therapeutics AARD Stock Holding History
Bought
Maintained
Sold
Other funds holding AARD
Tower Research Capital (TRC)'s AARD Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Aardvark Therapeutics (AARD) stake by 20% in Q3 2026, buying an estimated $2.99K and bringing the position to 2,991 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3944.
Tower Research Capital (TRC) first reported a position in AARD in Q2 2025 and has held it in 6 quarters since. The position peaked at $20.6K in Q1 2026. 76 funds tracked by Wall St. Rank hold AARD as of Q3 2026.
- Tower Research Capital (TRC) held 2,991 shares of Aardvark Therapeutics worth $15.8K as of Q3 2026.
- Tower Research Capital (TRC) bought 490 Aardvark Therapeutics shares in Q3 2026, an estimated $2.99K.
- Aardvark Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3944 holding.
- Tower Research Capital (TRC) first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 6 quarters since.
- Tower Research Capital (TRC)'s Aardvark Therapeutics position peaked at $20.6K in Q1 2026.
- 76 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.